By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

WAVE Life Sciences 

733 Concord Avenue

Cambridge  Massachusetts  02138  U.S.A.
Phone: 1-617-949-2900 Fax: 1-617-949-2901


SEARCH JOBS

WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.

YEAR FOUNDED:

2012

LEADERSHIP:

CEO: Paul Bolno

CFO: Keith Regnante

JOBS:

Please click here for Wave Life Sciences.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW WAVE LIFE SCIENCES:



Key Statistics


Email: info@wavelifesci.com
Ownership: Public

Web Site: WAVE Life Sciences
Employees:
Symbol: WVE
 



Industry
Biotechnology






Company News
WAVE Life Sciences (WVE) Announces Publication Of Paper In Nature Biotechnology Establishing The Importance Of Stereochemical Purity In Oligonucleotide Drug Design 8/22/2017 7:23:15 AM
WAVE Life Sciences (WVE) Reports Second Quarter 2017 Financial Results And Provides Business Update 8/9/2017 6:30:48 AM
WAVE Life Sciences (WVE) Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 And PRECISION-HD2 In Patients With Huntington’s Disease 7/17/2017 6:14:29 AM
ReadCoor And WAVE Life Sciences (WVE) Initiate Research Collaboration 6/8/2017 7:01:16 AM
WAVE Life Sciences (WVE) Reports First Quarter 2017 Financial Results And Provides Business Update 5/10/2017 8:20:16 AM
WAVE Life Sciences (WVE) Prices Public Offering Of 4,166,667 Ordinary Shares 4/12/2017 11:41:26 AM
WAVE Life Sciences (WVE) Announces Proposed Public Offering Of Ordinary Shares 4/12/2017 6:35:10 AM
WAVE Life Sciences (WVE) Reports Fourth Quarter And Full-Year 2016 Financial Results And Provides Business Update 3/16/2017 6:11:08 AM
nLife Therapeutics Enters Research Collaboration With WAVE Life Sciences (WVE) To Explore Targeting Of Nucleic Acids To Specific Cell-Types In The Central Nervous System 3/3/2017 10:24:37 AM
WAVE Life Sciences (WVE) 2017 Pipeline Update 1/9/2017 12:57:04 PM
1234
//-->